Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
3348 results about "Biomarker (petroleum)" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Biomarkers are any of a suite of complex organic compounds composed of carbon, hydrogen and other elements such as oxygen, nitrogen and sulfur, which are found in crude oils, bitumens, petroleum source rock and eventually show simplification in molecular structure from the parent organic molecules found in all living organisms. Essentially, they are complex carbon-based molecules derived from formerly living organisms. Biomarker compounds are typically analyzed using gas chromatography and mass spectrometry. Some examples of biomarkers found in petroleum are pristane, phytane, steranes, triterpanes and porphyrin. Geologists and Geochemists use biomarkers traces found in crude oils and their related source rock to unravel the stratigraphic origin and migration pathways of presently existing petroleum deposits.However, Biomarker analysis of untreated rock cuttings can be expected to produce misleading results. This is due to potential hydrocarbon contamination and biodegradation in the rock samples.
Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
InactiveUS20100172874A1Decreasing energy harvestingGood for weight lossBiocideMetabolism disorderDiseaseMicroorganism
The present invention relates to the gut microbiome as a biomarker and therapeutic target for energy harvesting, weight loss or gain, and / or obesity in a subject. In particular, the invention provides methods of altering and monitoring the relative abundance of Bacteroides and Firmicutes in the gut microbiome of a subject.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Prediction of prostate cancer progression by analysis of selected predictive parameters
InactiveUS6025128AImprove performanceMicrobiological testing/measurementBiological testingStatistical analysisFactor ii
A method for screening individuals at risk for prostate cancer progression is disclosed. The method is useful for evaluating cells from patients at risk for recurrence of prostate cancer following surgery for prostate cancer. Specifically, the method uses specific Markovian nuclear texture factors, alone or in combination with other biomarkers, to determine whether the cancer will progress or lose organ confinement. In addition, methods of predicting the development of fatal metastatic disease by statistical analysis of selected biomarkers is also disclosed. The invention also contemplates a method that uses a neural network to analyze and interpret cell morphology data. Utilizing Markovian factors and other biomarkers as parameters, the network is first trained with a sets of cell data from known progressors and known non-progressors. The trained network is then used to predict prostate cancer progression in patient samples.
Owner:CYTODIAGNOSTICS +3
Method and Apparatus for the Treatment of Movement Disorders
A method, apparatus, and system for treating patients suffering from movement disorders having the ability to determine one or more biomarkers indicative of a disease state. In some embodiments, the biomarker may be used as a closed-loop feedback signal to control the delivery of therapy (such as electrical stimulation or drug therapy), and which may also be used as an indication of therapy effectiveness. One embodiment uses electrodes placed in the brain to measure EEG or local field potential (LFP) signals, from which the one or more biomarkers may be determined.
Owner:MEDTRONIC INC
Methods of monitoring conditions by sequence analysis
ActiveUS20100151471A1Maximize correlationMicrobiological testing/measurementBiological testingSequence analysisAutoimmune disease
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions. Identified biomarkers can be used to determine the disease state for a subject with an autoimmune disease or other condition.
Owner:ADAPTIVE BIOTECH
Biomarker generator system
ActiveUS7476883B2Efficient dosingEfficient productionMaterial analysis using wave/particle radiationIsotope delivery systemsChemical synthesisMicroreactor
Owner:BEST ABT INC
Monitoring health and disease status using clonotype profiles
ActiveUS20110207134A1High sensitivityOvercome deficienciesMicrobiological testing/measurementAutoimmune diseaseBiomarker (petroleum)
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and / or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.
Owner:ADAPTIVE BIOTECH
Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers
ActiveUS7919264B2Better assess improvements in the patient's disease statusUseful in treatingBioreactor/fermenter combinationsBiological substance pretreatmentsAnkylosing spondylitisAntigen binding
The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and / or a synovitis biomarker.
Owner:AMERICAN TELEPHONE & TELEGRAPH CO +1
BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFalpha INHIBITORS IN AUTOIMMUNE DISORDERS
ActiveUS20090017472A1Prediction of responsivenessAntipyreticMicrobiological testing/measurementDiseaseAutoimmune responses
The invention provides methods for predicting responsiveness to TNFα inhibitors in a subject suffering from an autoimmune disorder, such as rheumatoid arthritis. The methods involve assaying for expression of one or more biomarkers in the subject that are predictive of responsiveness to TNFα inhibitors. A preferred biomarker of the invention is CD11c. The methods can further comprise selecting a treatment regimen with a TNFα inhibitor in an autoimmune disorder subject based upon expression of the biomarker(s) in the subject. The methods can further comprise administering a TNFα inhibitor to the subject according to the selected treatment regimen. Kits that include means for measuring expression of one or more biomarkers that are predictive of responsiveness to TNFα inhibitors for an autoimmune disorder are also provided. Methods of preparing and using databases, and computer program products therefore, for selecting an autoimmune disorder subject for treatment with a TNFα inhibitor are also provided.
Owner:ABBVIE INC
Monitoring health and disease status using clonotype profiles
ActiveUS8748103B2High sensitivityOvercome deficienciesMicrobiological testing/measurementFermentationAutoimmune diseaseBiomarker (petroleum)
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and / or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.
Owner:ADAPTIVE BIOTECH
Simulating patient-specific outcomes
InactiveUS20050131663A1Timing is simpleMedical simulationAnalogue computers for chemical processesEfficacyBiomarker (petroleum)
The invention encompasses systems, methods, and apparatus for predicting and monitoring an individual's response to a therapeutic regimen. The invention includes multiple virtual patients, an associating subsystem operable to associate the subject with one or more of the virtual patients, and a simulation engine operable to apply one or more experimental protocols to the one or more virtual patients identified with the subject to generate a set of outputs. The set of outputs can represent therapeutic efficacy, identify biomarkers for monitoring therapeutic efficacy, or merely report the status of the biological system as it represents a particular individual
Owner:ENTELOS HLDG
Selection of cells using biomarkers
InactiveUS20080113358A1Easy to separateIncrease the number ofMicrobiological testing/measurementMaterial analysisFetal abnormalityFetal cell
The present invention provides systems, apparatuses, and methods to isolate, select or detect the presence of a target cell (e.g., fetal cells) in a sample comprising mixed populations of cells that vastly outnumber the target cells. Target cells include fetal cells, such as nucleated red blood cells, and methods of selecting such cells include diagnosis of fetal abnormalities, i.e., aneuploidy. Furthermore, methods comprise utilizing fetal biomarkers to select fetal cells in a sample comprising fetal and adult cells.
Owner:THE GENERAL HOSPITAL CORP +2
Biomarkers for predicting prostate cancer progression
InactiveUS20060234259A1Useful predictionCompound screeningApoptosis detectionProstate cancerOncology
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Methods and compositions for the detection of cervical disease
ActiveUS20050260566A1Improve the level ofIncreased proliferationAnimal cellsMicrobiological testing/measurementDiseaseCervical cells
Methods and compositions for identifying high-grade cervical disease in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in high-grade cervical disease. In particular claims, the body sample is a cervical smear or monolayer of cervical cells. The biomarkers of the invention include genes and proteins that are involved in cell cycle regulation, signal transduction, and DNA replication and transcription. In particular claims, the biomarker is an S-phase gene. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.
Owner:TRIPATH IMAGING INC
Biomarkers useful for diagnosing prostate cancer, and methods thereof
InactiveUS20090127454A1Improve diagnostic capabilitiesImpact to detectParticle separator tubesComponent separationMetaboliteProstate cancer
The present invention describes a method for predicting a health-state indicative of the presence of prostate cancer. The method measures the intensities of specific small biochemicals, called metabolites, in a blood sample from a patient with an undetermined health-state, and compares these intensities to the intensities observed in a population of healthy individuals and / or to the intensities previously observed in a population of confirmed prostate cancer-positive individuals. The method enables a practitioner to determine the probability that a screened patient is positive for prostate cancer.
Owner:MED LIFE DISCOVERIES LP
Application of nanotechnology and sensor technologies for ex-vivo diagnostics
InactiveUS7052854B2Easy diagnosisQuick checkMicrobiological testing/measurementMaterial analysis by electric/magnetic meansAnalyteBody fluid
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Methods of macromolecular analysis using nanochannel arrays
ActiveUS20080242556A1Microbiological testing/measurementLibrary screeningGenomic DNABiomarker (petroleum)
Methods of analyzing features such as the physical size of macromolecules or biomarkers along large genomic DNA molecules were disclosed as well as the devices for carrying out such high throughput analysis in a massively parallel fashion. Methods of fabricating such devices are also disclosed.
Owner:BIONANO GENOMICS
Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
InactiveUS20070212738A1Restore sensitivityHigh sensitivityDisease diagnosisAntineoplastic agentsEpidermal Growth Factor Receptor KinaseKinase
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and / or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided.
Owner:OSI PHARMA LLC
Fluorescent Methods and Materials for Directed Biomarker Signal Amplification
ActiveUS20080293164A1Solid-state devicesPharmaceutical non-active ingredientsFluorescenceChromogenic
Methods and compositions are provided that include a multichromophore and / or multichromophore complex for identifying a target biomolecule. A sensor biomolecule, for example, an antibody can be covalently linked to the multichromophore. Additionally, a signaling chromophore can be covalently linked to the multichromophore. The arrangement is such that the signaling chromophore is capable of receiving energy from the multichromophore upon excitation of the multichromophore. Since the sensor biomolecule is capable of interacting with the target biomolecule, the multichromophore and / or multichromophore complex can provide enhanced detection signals for a target biomolecule.
Owner:SIRIGEN
Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
Owner:WASHINGTON UNIV IN SAINT LOUIS
Personalized Tumor Biomarkers
ActiveUS20150344970A1Microbiological testing/measurementLibrary member identificationBlood plasmaWilms' tumor
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Identification of biomarkers for detecting pancreatic cancer
InactiveUS20050095611A1Microbiological testing/measurementMaterial analysisOncologyBiomarker (petroleum)
The present invention relates to a method of qualifying pancreatic cancer status in a subject comprising: (a) measuring at least one of the disclosed biomarkers in a sample from the subject and (b) correlating the measurement with pancreatic cancer status. The invention further relates to kits for qualifying pancreatic cancer status in a subject.
Owner:CHAN DANIEL +6
Analyte detection with magnetic sensors
ActiveUS20090104707A1Material analysis by electric/magnetic meansBiological testingDisease markersAnalyte
Methods for analyte detection with magnetic sensors are provided. Aspects of the methods include producing a magnetic sensor device having a magnetically labeled analyte from a sample, such as a serum sample, bound to a surface of a magnetic sensor thereof; and obtaining a signal, e.g., a real-time signal, from the magnetic sensor to determine whether the analyte is present in the sample. Also provided are devices, systems and kits that find use in practicing the methods of the invention. The methods, devices, systems and kits of the invention find use in a variety of different applications, including detection of biomarkers, such as disease markers.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Conjunctive analysis of biological marker expression for diagnosing organ failure
InactiveUS6461828B1Easy to useHigh riskAnalysis using chemical indicatorsEnzymologyOrgan systemOrganism
A diagnostic tool is disclosed for accurately and rapidly diagnosing the condition of an ailing organ. Although applicable to numerous organ and organ systems, this application particularly illustrates the concept of conjunctive marker utilization as it relates to diagnosing and distinguishing congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTn-I) and natriuretic peptide, e.g. ANP, pro-ANP, BNP, pro-BNP and CNP as a retrospective tool for diagnosing the underlying mechanism of heart failure and as a prospective analytical device for monitoring disease progression and efficacy of therapeutic agents.
Owner:SYN X PHARMA
Monitoring health and disease status using clonotype profiles
ActiveUS8628927B2High sensitivityOvercome deficienciesMicrobiological testing/measurementUnknown materialsAutoimmune diseaseLymphatic neoplasm
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and / or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.
Owner:ADAPTIVE BIOTECH
Method for the early detection of renal injury
A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +1
Chemical Compositon And Its Devlivery For Lowering The Risks Of Alzheimer's Cardiovascular And Type -2 Diabetes Diseases
ActiveUS20160004298A1Reduce riskInput/output for user-computer interactionTelevision system detailsThe InternetBiomarker (petroleum)
Chemical compositions of bioactive compounds and / or bioactive molecules for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases are described. Targeted, passive and programmable / active deliveries of the bioactive compounds and / or bioactive molecules are described. Many embodiments of various subsystems for detection of disease specific biomarkers / an array of disease specific biomarkers and programmable / active delivery of the bioactive compounds and / or bioactive molecules in near real-time / real-time are also described. A portable internet appliance, a portable internet cloud appliance and an augmented reality personal assistant subsystem are also described along with various applications.
Owner:MAZED MOHAMMAD A +1
Carbon monoxide as a biomarker and therapeutic agent
InactiveUS20020155166A1Reduce concentrationBiocideInorganic active ingredientsInterstitial lung diseaseRESPIRATORY DISTRESS SYNDROME ADULT
The present invention relates to the use of carbon monoxide (CO) as a biomarker and therapeutic agent of heart, lung, liver, spleen, brain, skin and kidney diseases and other conditions and disease states including, for example, asthma, emphysema, bronchitis, adult respiratory distress syndrome, sepsis, cystic fibrosis, pneumonia, interstitial lung diseases, idiopathic pulmonary diseases, other lung diseases including primary pulmonary hypertension, secondary pulmonary hypertension, cancers, including lung, larynx and throat cancer, arthritis, wound healing, Parkinson's disease, Alzheimer's disease, peripheral vascular disease and pulmonary vascular thrombotic diseases such as pulmonary embolism. CO may be used to provide anti-inflammatory relief in patients suffering from oxidative stress and other conditions especially including sepsis and septic shock. In addition, carbon monoxide may be used as a biomarker or therapeutic agent for reducing respiratory distress in lung transplant patients and to reduce or inhibit oxidative stress and inflammation in transplant patients.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Biomarker assay for diagnosis and classification of cardiovascular disease
InactiveUS20110144914A1Reduce controlLow variabilityMicrobiological testing/measurementOmicsCardiovascular healthBiomarker (petroleum)
The disclosed methods, assays and kits identify biomarkers, particularly miRNA and / or protein biomarkers, for assessing the cardiovascular health of a human. In certain embodiments, methods, assays and kits, circulating miRNA and / or protein biomarkers are identified for assessing the cardiovascular health of a human.
Owner:AVIIR +1
Two biomarkers for diagnosis and monitoring of atherosclerotic cardiovascular disease
The present invention identifies two circulating proteins that have been newly identified as being differentially expressed in atherosclerosis. Circulating levels of these two proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.
Owner:AVIIR +1
Method and Apparatus for Detecting Irregularities in Tissue Microarrays
The present techniques provide systems and methods for registering images of tissue spots on a tissue microarray (TMA). In studies involving multiple biomarkers being studied on the same TMA, the TMA slide is removed from the microscope, stained, and then imaged, often multiple times. The present techniques relate to validation of the registration of the acquired images of the same TMA. An automatic approach to register the images and detect registration failures as provided herein may enhance the rapid analysis of the tissues. Artifacts such as tissue folding and tissue loss are also determined automatically.
Owner:GENERAL ELECTRIC CO
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com